Breaking Meta Ordered to Pay $567 Million for Youth Mental Health Impacts Donald Trump’s Enduring Fascination With Grass Takes Center Stage Health Workers Strike Amidst Growing Ebola Outbreak in Democratic Republic of Congo Caitlin Clark Accepts Blame for Indiana Fever’s Overtime Loss to Las Vegas Aces Dozens of Elephants Die in Amboseli National Park Amid Poisoning Concerns

Friday August 7, 2026

Reporter

Ascletis Pharma Inc.

2Articles Published

4Communities Covered

Published Articles

Press Release

Ascletis Announces Initiation of Global Phase III for Oral Small Molecule GLP-1, ASC30 and Positive Preclinical Data for Its First-in-Class Oral Small Molecule GLP-1/GIP/Amylin Fixed-Dose Combination

Aug 3

Press Release

Ascletis Announces Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, Demonstrated Superior Weight Loss in a Diet-Induced Obese Mouse Model

Jul 27